22 related articles for article (PubMed ID: 15715968)
1. Synthesis and biological evaluation of 2-styrylquinolines as antitumour agents and EGFR kinase inhibitors: molecular docking study.
El-Sayed MA; El-Husseiny WM; Abdel-Aziz NI; El-Azab AS; Abuelizz HA; Abdel-Aziz AA
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):199-209. PubMed ID: 29251017
[TBL] [Abstract][Full Text] [Related]
2. The marine-derived oligosaccharide sulfate (MdOS), a novel multiple tyrosine kinase inhibitor, combats tumor angiogenesis both in vitro and in vivo.
Ma J; Xin X; Meng L; Tong L; Lin L; Geng M; Ding J
PLoS One; 2008; 3(11):e3774. PubMed ID: 19020661
[TBL] [Abstract][Full Text] [Related]
3. Establishment of the active catalytic domain of human PDGFRbeta tyrosine kinase-based ELISA assay for inhibitor screening.
Zhang XH; Guo XN; Zhong L; Luo XM; Jiang HL; Lin LP; Ding J
Biochim Biophys Acta; 2007 Oct; 1770(10):1490-7. PubMed ID: 17719179
[TBL] [Abstract][Full Text] [Related]
4. Expression and purification of human vascular-endothelial-growth-factor-receptor-2 tyrosine kinase in Streptomyces for inhibitor screening.
Liu C; Guo L; Yao C; Zhang R; Li Y
Biotechnol Appl Biochem; 2008 Jun; 50(Pt 2):113-9. PubMed ID: 17824843
[TBL] [Abstract][Full Text] [Related]
5. Soluble Expression and Purification of the Catalytic Domain of Human Vascular Endothelial Growth Factor Receptor 2 in Escherichia coli.
Wei J; Cao X; Zhou S; Chen C; Yu H; Zhou Y; Wang P
J Microbiol Biotechnol; 2015 Aug; 25(8):1227-33. PubMed ID: 25907066
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.
Beebe JS; Jani JP; Knauth E; Goodwin P; Higdon C; Rossi AM; Emerson E; Finkelstein M; Floyd E; Harriman S; Atherton J; Hillerman S; Soderstrom C; Kou K; Gant T; Noe MC; Foster B; Rastinejad F; Marx MA; Schaeffer T; Whalen PM; Roberts WG
Cancer Res; 2003 Nov; 63(21):7301-9. PubMed ID: 14612527
[TBL] [Abstract][Full Text] [Related]
7. Transactivation of KDR/Flk-1 by the B2 receptor induces tube formation in human coronary endothelial cells.
Miura S; Matsuo Y; Saku K
Hypertension; 2003 May; 41(5):1118-23. PubMed ID: 12654712
[TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor receptors: molecular mechanisms of activation and therapeutic potentials.
Rahimi N
Exp Eye Res; 2006 Nov; 83(5):1005-16. PubMed ID: 16713597
[TBL] [Abstract][Full Text] [Related]
9. Small molecule inhibitors of KDR (VEGFR-2) kinase: an overview of structure activity relationships.
Boyer SJ
Curr Top Med Chem; 2002 Sep; 2(9):973-1000. PubMed ID: 12171566
[TBL] [Abstract][Full Text] [Related]
10. Property-based design of KDR kinase inhibitors.
Fraley ME; Hoffman WF; Arrington KL; Hungate RW; Hartman GD; McFall RC; Coll KE; Rickert K; Thomas KA; McGaughey GB
Curr Med Chem; 2004 Mar; 11(6):709-19. PubMed ID: 15032725
[TBL] [Abstract][Full Text] [Related]
11. Expression and purification of the catalytic domain of human vascular endothelial growth factor receptor 2 for inhibitor screening.
Zhong L; Guo XN; Zhang XH; Wu ZX; Luo XM; Jiang HL; Lin LP; Zhang XW; Ding J
Biochim Biophys Acta; 2005 Apr; 1722(3):254-61. PubMed ID: 15715968
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
